Related Experiment Video
Updated: Jun 19, 2026
05:15
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
Vagal stimulation for heart failure: background and first in-man study
Peter J Schwartz1, Gaetano M De Ferrari
1Section of Cardiology, Department of Lung, Blood and Heart, University of Pavia, Pavia, Italy. peter.schwartz@unipv.it
Heart Rhythm
|November 3, 2009
Summary
Direct chronic vagal stimulation is a feasible and safe new treatment for heart failure. Early results show potential benefits in patients with advanced heart failure, warranting further investigation.
Area of Science:
- Cardiology
- Neuroscience
- Biomedical Engineering
Background:
- Autonomic imbalance is implicated in heart failure pathophysiology.
- Animal studies demonstrate the efficacy of vagal stimulation in improving outcomes.
- Depressed vagal reflexes correlate with poor prognosis in heart failure.
Purpose of the Study:
- To review the rationale for initiating the first human study of direct chronic vagal stimulation for heart failure.
- To present and analyze data from the initial pilot trial in human subjects.
Main Methods:
- Eight patients with advanced heart failure were enrolled.
- A neurostimulator system was implanted to deliver electrical pulses to the right vagus nerve.
- The system provided low-current electrical pulses for chronic vagal stimulation.
Main Results:
- Chronic vagal stimulation in humans was found to be feasible and safe.
- Initial data suggest the treatment is associated with beneficial effects in heart failure patients.
- The pilot study provides preliminary evidence for the therapeutic potential of vagal stimulation.
Conclusions:
- Direct chronic vagal stimulation is a safe and feasible approach for managing heart failure.
- This innovative therapy shows promise for improving outcomes in patients with advanced heart failure.
- Further research is warranted to confirm the long-term efficacy and benefits of vagal stimulation.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...